One of the only good transparency innovations of the Trump era has come to a quiet end.

Industry giants and cellular-meat upstarts are in a lobbying war over consumer labeling.

The same day Earthshot awarded $1.2 million to start-up Notpla and its petroleum-free seaweed packaging, negotiations to curb plastics production failed miserably.

Households preparing for a 30 percent price hike may not know their dollars are going to trade associations that oppose the very changes that could reduce their bills in future.

Embracing the bitcoin industry’s regulatory agenda is not the answer to the crypto crash.

Borrowing a page from the fossil fuel industry’s playbook, meat’s “merchants of doubt” are funding questionable research and lobbying to keep meat reduction off the table.

A new piece of bipartisan legislation seeks to purge This Town of foreign influence peddling—all of it.

Trump’s son-in-law may be the hot new player in Washington’s seamy influence-peddling game, but he’s following in the footsteps of many of the Beltway’s major players.

Texas Congressman Henry Cuellar’s not the only lawmaker illicitly involved with the regime, he’s just the one who (maybe) got caught.

The president has the power to reform the wayward Tennessee Valley Authority. It’s a bigger deal than you think.

One of the best ideas in Build Back Better is dead, and the higher-ed lobby deserves some blame.

The industry’s titanic profits power a perpetual stranglehold over our government with only one goal in mind: raking you clean of every last dime.

The FDA should be our toughest regulatory body, but the pharmaceutical lobby has torn it to shreds.

The Democratic lawyer’s sickening defense of corporate immunity in a Supreme Court case reveals a growing moral rot in the legal community.

He’s threatened to jam Washington’s revolving door, and the influence-peddlers are in hysterics.

The ride-share firms push regressive labor and transportation policies—and they’re stocked with Obama alumni. Would Biden welcome or blacklist them?

Nationalize them.

After years of undermining health policy to aid their Big Pharma patrons, patient advocacy groups are making claims to federal pandemic relief.

As the coronavirus racks the globe, White House lackeys and lobbyists are converging on the former Yugoslavia and reopening old wounds.

One man’s crusade to sell big business on a health care overhaul